Eli Lilly's stock has been receiving many upgrades after posting strong quarterly results in February.

Barclays reaffirmed its ‘Overweight’ rating on the LLY stock and its $1,350 price target on Tuesday, according to a TipRanks ...

Eli Lilly's stock is down this year, and its high valuation may be a big reason why.

Eli Lilly (NYSE:LLY) stock is down 5% in Tuesday afternoon trading, with shares falling to $937 from a prior close of $989.12 ...

Eli Lilly’s growth is heavily dependent on weight loss drugs. The healthcare sector is reasonably valued. Eli Lilly makes ...

What HSBC just said about Eli Lilly stock. Well, technically, the word HSBC used was "reduce," but it amounts to the same ...

Eli Lilly (LLY) stock drops as HSBC downgrades the company warning that weight-loss drugmaker could be “priced to perfection.

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The company still has a robust business that is delivering excellent results and ...

Eli Lilly (LLY) stock declined after HSBC downgrade to Reduce with $850 price target, citing obesity drug market risks and ...

Eli Lilly (NYSE: LLY) is close to doing something no other pharmaceutical company has ever done: reaching $1 trillion in market value. The company briefly touched that level in November but has since ...

The Eli Lilly logo appears on a laptop computer screen in this photo illustration in Athens, Greece, on February 9, 2026. Vaccine manufacturers play a central role in global public health, investing ...